m-Chloroperbenzoic acid → 2-[[3-Methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-6-fluoro-5-(piperidin-1-yl)-1H-benzimidazole

Participants

Reaction Steps

The title compound (0.18 g, 78%) was prepared by the above general procedure using 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylthio]-6-fluoro-5-(piperidin-1-yl)-1H-benzimidazole (0.23 g, 0.5 mmol) (obtained in example 16), m-chloroperbenzoic acid (50%, 0.2 g, 0.6 mmol) and chloroform (20 mL). mp 99-100° C.; IR (KBr) 3413, 1070 cm- 1; 1H NMR (DMSO-d6) δ 1.52 (m, 2H, CH2), 1.70 (m, 4H, (CH2)2), 2.20 (s, 3H, CH3) 3.98 (t,J=4.5 Hz, 4H, N(CH2)2), 4.80 (ABq,J=12.9 Hz, Δv=9.1 Hz, 2H, SOCH2), 4.94 (q,J=8.1 Hz, 2H, OCH2CF3), 7.12 (d,J=5.8 Hz, 1H), 7.18 (d,J=7.8 Hz, 1H), 7.44 (d,J=12.7 Hz, 1H), 8.32 (d,J=5.5 Hz, 1H); Mass (m/z) 454 (M -16).

Provenance & Evidence